Matthew L Holzner
Overview
Explore the profile of Matthew L Holzner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
148
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tabrizian P, Holzner M, Ajmera V, Kim A, Zhou K, Schnickel G, et al.
J Hepatol
. 2024 Sep;
82(3):512-522.
PMID: 39255928
Background & Aims: The use of immune checkpoint inhibitors (ICIs) in patients with advanced hepatocellular carcinoma (HCC) has become widespread with encouraging outcomes in the neoadjuvant setting. Safety and intention-to-treat...
2.
Holzner M, Mazzaferro V, Droz Dit Busset M, Aldrighetti L, Ratti F, Hasegawa K, et al.
Ann Surg Oncol
. 2024 Feb;
31(7):4397-4404.
PMID: 38334851
Background: Recurrence of intrahepatic cholangiocarcinoma (ICC) after liver resection (LR) remains high, and optimal therapy for recurrent ICC is challenging. Herein, we assess the outcomes of patients undergoing repeat resection...
3.
Tabrizian P, Holzner M, Zaret D, Meyerovich G, Fagenson A, Schiano T
Ann Palliat Med
. 2023 Dec;
13(1):126-140.
PMID: 38124475
Background And Objective: Hepatocellular carcinoma (HCC) is a leading cause of morbidity and mortality in the United States. For certain patients, liver transplantation (LT) may be curative. The determination of...
4.
Holzner M, Palese M, Florman S
Clin Transplant
. 2023 Aug;
37(11):e15095.
PMID: 37572316
No abstract available.
5.
Uzarski J, Beck E, Russell E, Vanderslice E, Holzner M, Wadhera V, et al.
Front Bioeng Biotechnol
. 2023 Jun;
11:1184408.
PMID: 37388767
Despite progress in whole-organ decellularization and recellularization, maintaining long-term perfusion remains a hurdle to realizing clinical translation of bioengineered kidney grafts. The objectives for the present study were to define...
6.
Tabrizian P, Holzner M, Mehta N, Halazun K, Agopian V, Yao F, et al.
JAMA Surg
. 2022 Jul;
157(9):779-788.
PMID: 35857294
Importance: National guidelines on transplant selection have adopted successful downstaging to within Milan criteria (MC) as a viable option for the treatment of hepatocellular carcinoma (HCC) before liver transplant (LT)....
7.
Tabrizian P, Saberi B, Holzner M, Rocha C, Jung Y, Myers B, et al.
HPB (Oxford)
. 2021 Dec;
24(7):1082-1090.
PMID: 34955348
Background: The development of direct-acting antiviral (DAA) therapy has revolutionized HCV management. We present a large national study comparing post-LT outcomes for HBV-HCC vs. HCV-HCC according to DAA era. Methods:...
8.
Tabrizian P, Holzner M, Adamson D, Balci D, Jung Y, Arnon R, et al.
HPB (Oxford)
. 2021 Nov;
24(6):817-824.
PMID: 34742650
Background: Outcomes of left lateral segment (LLS) grafts in pediatric recipients were compared between living (LD-LLS) and deceased donor (DD-LLS) grafts. Methods: 195 LLS grafts (99DD-LLS-96LD-LLS) were analyzed with a...
9.
Holzner M, Florman S, Schwartz M, Tabrizian P
HPB (Oxford)
. 2021 Sep;
24(4):470-477.
PMID: 34544629
Background: Nonalcoholic steatohepatitis-associated hepatocellular carcinoma (NASH-HCC) is the second-leading cause of liver transplantation (LT) performed for HCC. Despite this, little is known about the clinical characteristics and outcomes of NASH-HCC....
10.
Mehta N, Frenette C, Tabrizian P, Hoteit M, Guy J, Parikh N, et al.
Gastroenterology
. 2021 Jul;
161(5):1502-1512.
PMID: 34331914
Background & Aims: United Network of Organ Sharing (UNOS) has adopted uniform criteria for downstaging (UNOS-DS) of hepatocellular carcinoma (HCC) before liver transplantation (LT), but the downstaging success rate and...